{"id":"tp-54255","type":"article-newspaper","title":"Beam Therapeutics Reports Positive Topline Data From Sickle Cell Trial","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/54255","datePublished":"2026-11-11T17:19:02.000Z","dateModified":"2026-11-11T17:19:02.000Z","language":"en","abstract":"The Phase 1/2 BEACON study met its primary efficacy endpoint and all primary safety endpoints at an interim analysis.","section":"Business","references":[]}